Ignite Creation Date:
2024-07-17 @ 11:13 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06484972
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-06-26
Brief Title:
A Multicenter Cluster Randomized Controlled Study to Evaluate Guideline Adoption Through Lung Cancer Clinical Care Quality Improvement Project QIP in Pulmonary and Critical Care Medicine PCCM Department
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Multicenter Cluster Randomized Controlled Study to Evaluate Guideline Adoption Through Lung Cancer Clinical Care Quality Improvement Project QIP in Pulmonary and Critical Care Medicine PCCM Department
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LC PCCM QIP
Brief Summary:
This is a cluster randomized controlled trial with PCCM department in each site being the cluster Fifty-four sites PCCM departments will be randomized to the QIP arm versus control arm in 21 allocation ratio The QIP arm will perform QIP intervention The control arm will not receive intervention and continue with usual care
The primary endpoints of this study are molecular testing rate of non-small cell lung cancer NSCLC prior to the first systematic anti-tumor therapy and adjuvant or first line targeted therapy treatment rate in actionable oncogenic alterations AGA NSCLC
The primary endpoints of this study are molecular testing rate of non-small cell lung cancer NSCLC prior to the first systematic anti-tumor therapy and adjuvant or first line targeted therapy treatment rate in actionable oncogenic alterations AGA NSCLC
Detailed Description:
Approximately 1728 patients from 54 sites will be enrolled about 30 NSCLC 20-30 squamous cases and 2 extensive-stage small-cell lung cancer ES-SCLC patients in each site Patients in the QIP arm will be enrolled after about 3-month QIP intervention Patients in the control arm will be enrolled as soon as the trial starts Data on lung cancer diagnosis and treatment pattern will be collected
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None